You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethotrimeprazine
Accession NumberDB01403
TypeSmall Molecule
GroupsApproved
DescriptionA phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Structure
Thumb
Synonyms
(-)-(2R)-3-(2-Methoxy-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine
(-)-10-(3-(Dimethylamino)-2-methylpropyl)-2-methoxyphenothiazine
2-Methoxytrimeprazine
Levomepromazina
Levomepromazine
Levomepromazinum
Methotrimeprazine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methoprazinetablet5 mgoralAa Pharma Inc1998-07-20Not applicableCanada
Methoprazinetablet25 mgoralAa Pharma Inc1998-07-20Not applicableCanada
Methoprazinetablet50 mgoralAa Pharma Inc1998-07-20Not applicableCanada
Methoprazinetablet2 mgoralAa Pharma Inc1998-07-20Not applicableCanada
Methotrimeprazine-2tablet2 mgoralPro Doc Limitee1999-05-102009-07-23Canada
Methotrimeprazine-25tablet25 mgoralPro Doc Limitee1999-05-122011-07-27Canada
Methotrimeprazine-5tablet5 mgoralPro Doc Limitee1999-05-122011-07-27Canada
Methotrimeprazine-50tablet50 mgoralPro Doc Limitee1999-05-102011-07-27Canada
Nov Meprazine Tab 50mgtablet50 mgoralNovopharm Limited1996-12-312005-08-10Canada
Novo Meprazine Tab 25mgtablet25 mgoralNovopharm Limited1996-12-31Not applicableCanada
Novo Meprazine Tab 5mgtablet5 mgoralNovopharm Limited1995-07-17Not applicableCanada
Nozinan 5mg Tabtablet5 mgoralSanofi Aventis Canada Inc1958-12-312007-07-18Canada
Nozinan 5mg/mlsolution5 mgoralSanofi Aventis Canada Inc1966-12-312006-07-28Canada
Nozinan Inj 25mg/mlsolution25 mgintramuscular; intravenousSanofi Aventis Canada Inc1958-12-31Not applicableCanada
Nozinan Liq 40mg/mldrops; liquid40 mgoralAventis Pharma Inc1963-12-312005-08-01Canada
Nozinan Tab 25mgtablet25 mgoralSanofi Aventis Canada Inc1958-12-312007-07-18Canada
Nozinan Tab 2mgtablet2 mgoralAventis Pharma Inc1958-12-312005-08-01Canada
Nozinan Tab 50mgtablet50 mgoralSanofi Aventis Canada Inc1958-12-312007-07-18Canada
PMS-methotrimeprazinetablet25 mgoralPharmascience Inc1997-10-20Not applicableCanada
PMS-methotrimeprazinetablet50 mgoralPharmascience Inc1997-10-20Not applicableCanada
PMS-methotrimeprazinetablet5 mgoralPharmascience Inc1997-10-20Not applicableCanada
Riva-meprazine 25mg Tabletstablet25 mgoralLaboratoire Riva Inc1999-11-222003-07-28Canada
Riva-meprazine 50mg Tabletstablet50 mgoralLaboratoire Riva Inc1999-11-222003-07-28Canada
Riva-meprazine 5mg Tabletstablet5 mgoralLaboratoire Riva Inc1999-11-222003-07-28Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LevopromeNot Available
NeurocilNot Available
NosinanNot Available
NozinanNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII9G0LAW7ATQ
CAS number60-99-1
WeightAverage: 328.472
Monoisotopic: 328.16093409
Chemical FormulaC19H24N2OS
InChI KeyInChIKey=VRQVVMDWGGWHTJ-CQSZACIVSA-N
InChI
InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1
IUPAC Name
[(2R)-3-(2-methoxy-10H-phenothiazin-10-yl)-2-methylpropyl]dimethylamine
SMILES
COC1=CC2=C(SC3=C(C=CC=C3)N2C[[email protected]](C)CN(C)C)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • Anisole
  • Alkyl aryl ether
  • Benzenoid
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder.
PharmacodynamicsMethotrimeprazine is a phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Mechanism of actionMethotrimeprazine's antipsychotic effect is largely due to its antagonism of dopamine receptors in the brain. In addition, its binding to 5HT2 receptors may also play a role.
Related Articles
AbsorptionMethotrimeprazine has an incomplete oral bioavailability, because it undergoes considerable first-pass-metabolism in the liver. Oral bioavailability is approximately 50 to 60%.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. Methotrimeprazine is metabolized in the liver and degraded to a sulfoxid-, a glucuronid- and a demethyl-moiety.

Route of eliminationNot Available
Half lifeApproximately 20 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include convulsions, spastic movements, and coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9857
Blood Brain Barrier+0.9935
Caco-2 permeable+0.6694
P-glycoprotein substrateSubstrate0.6805
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8571
Renal organic cation transporterNon-inhibitor0.5132
CYP450 2C9 substrateNon-substrate0.7511
CYP450 2D6 substrateSubstrate0.5363
CYP450 3A4 substrateSubstrate0.6056
CYP450 1A2 substrateInhibitor0.6953
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.5432
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5633
Ames testNon AMES toxic0.5562
CarcinogenicityNon-carcinogens0.9182
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5064 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.932
hERG inhibition (predictor II)Inhibitor0.8488
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral2 mg
Tabletoral25 mg
Tabletoral5 mg
Solutionoral5 mg
Solutionintramuscular; intravenous25 mg
Drops; liquidoral40 mg
Tabletoral50 mg
Prices
Unit descriptionCostUnit
Nozinan 25 mg/ml3.6USD ml
Apo-Methoprazine 50 mg Tablet0.4USD tablet
Apo-Methoprazine 25 mg Tablet0.27USD tablet
Apo-Methoprazine 5 mg Tablet0.1USD tablet
Apo-Methoprazine 2 mg Tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility20 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.68HANSCH,C ET AL. (1995)
logS-4.22ADME Research, USCD
pKa9.19SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00525 mg/mLALOGPS
logP4.84ALOGPS
logP4.25ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)9.42ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area15.71 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity99.83 m3·mol-1ChemAxon
Polarizability36.77 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-056r-9356000000-bb17e4980980d336d337View in MoNA
References
Synthesis Reference

Christian Berger, “Process for preparing levomepromazine hydrogen maleate.” U.S. Patent US4798895, issued January 17, 1989.

US4798895
General References
  1. Link [Link]
External Links
ATC CodesN05AA02
AHFS Codes
  • 28:16.08.24
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineMethotrimeprazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineMethotrimeprazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Methotrimeprazine.
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Methotrimeprazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with 7-Nitroindazole.
AbirateroneThe metabolism of Methotrimeprazine can be decreased when combined with Abiraterone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Methotrimeprazine.
AcebutololMethotrimeprazine may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Methotrimeprazine.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methotrimeprazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Methotrimeprazine.
adipiplonThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Agomelatine.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Methotrimeprazine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Methotrimeprazine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Alfaxalone.
AlfentanilMethotrimeprazine may increase the hypotensive activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methotrimeprazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Methotrimeprazine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Methotrimeprazine.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Methotrimeprazine.
AlphacetylmethadolMethotrimeprazine may increase the hypotensive activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Methotrimeprazine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methotrimeprazine.
AlprenololMethotrimeprazine may increase the hypotensive activities of Alprenolol.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Methotrimeprazine.
AmiodaroneMethotrimeprazine may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Methotrimeprazine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methotrimeprazine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methotrimeprazine.
AmodiaquineThe serum concentration of Methotrimeprazine can be increased when it is combined with Amodiaquine.
AmoxapineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Amperozide.
AmphetamineMethotrimeprazine may decrease the stimulatory activities of Amphetamine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Methotrimeprazine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Methotrimeprazine.
AnagrelideMethotrimeprazine may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Methotrimeprazine.
AprindineThe metabolism of Aprindine can be decreased when combined with Methotrimeprazine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Methotrimeprazine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methotrimeprazine.
ArotinololMethotrimeprazine may increase the hypotensive activities of Arotinolol.
Arsenic trioxideMethotrimeprazine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherThe serum concentration of Methotrimeprazine can be increased when it is combined with Artemether.
ArtemetherMethotrimeprazine may increase the QTc-prolonging activities of Artemether.
ArtesunateThe serum concentration of Methotrimeprazine can be increased when it is combined with Artesunate.
ArticaineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Methotrimeprazine.
AtenololMethotrimeprazine may increase the hypotensive activities of Atenolol.
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Methotrimeprazine.
AtomoxetineThe metabolism of Methotrimeprazine can be decreased when combined with Atomoxetine.
AtovaquoneThe serum concentration of Methotrimeprazine can be increased when it is combined with Atovaquone.
AzaperoneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Azaperone.
AzelastineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Methotrimeprazine.
AzithromycinMethotrimeprazine may increase the QTc-prolonging activities of Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Barbital.
BedaquilineMethotrimeprazine may increase the QTc-prolonging activities of Bedaquiline.
BefunololMethotrimeprazine may increase the hypotensive activities of Befunolol.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Methotrimeprazine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Methotrimeprazine.
BenzphetamineMethotrimeprazine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Benzyl alcohol.
BepridilThe metabolism of Bepridil can be decreased when combined with Methotrimeprazine.
BetaxololMethotrimeprazine may increase the hypotensive activities of Betaxolol.
BetaxololThe metabolism of Methotrimeprazine can be decreased when combined with Betaxolol.
BevantololMethotrimeprazine may increase the hypotensive activities of Bevantolol.
BezitramideMethotrimeprazine may increase the hypotensive activities of Bezitramide.
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisoprololMethotrimeprazine may increase the hypotensive activities of Bisoprolol.
BopindololMethotrimeprazine may increase the hypotensive activities of Bopindolol.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Methotrimeprazine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
BrimonidineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Methotrimeprazine.
BrompheniramineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Brotizolam.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Methotrimeprazine.
BufuralolMethotrimeprazine may increase the hypotensive activities of Bufuralol.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methotrimeprazine.
BupranololMethotrimeprazine may increase the hypotensive activities of Bupranolol.
BuprenorphineMethotrimeprazine may increase the hypotensive activities of Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methotrimeprazine.
BupropionThe metabolism of Methotrimeprazine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methotrimeprazine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methotrimeprazine.
ButacaineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Methotrimeprazine.
ButorphanolMethotrimeprazine may increase the hypotensive activities of Butorphanol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methotrimeprazine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Methotrimeprazine.
CaffeineThe metabolism of Caffeine can be decreased when combined with Methotrimeprazine.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methotrimeprazine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Methotrimeprazine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methotrimeprazine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Carbinoxamine.
CarfentanilMethotrimeprazine may increase the hypotensive activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Methotrimeprazine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Methotrimeprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Carisoprodol.
CarteololMethotrimeprazine may increase the hypotensive activities of Carteolol.
CarvedilolMethotrimeprazine may increase the hypotensive activities of Carvedilol.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Methotrimeprazine.
CelecoxibThe metabolism of Methotrimeprazine can be decreased when combined with Celecoxib.
CeliprololMethotrimeprazine may increase the hypotensive activities of Celiprolol.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Methotrimeprazine.
CeritinibMethotrimeprazine may increase the QTc-prolonging activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Cetirizine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Methotrimeprazine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methotrimeprazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Methotrimeprazine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methotrimeprazine.
ChloroquineThe serum concentration of Methotrimeprazine can be increased when it is combined with Chloroquine.
ChloroquineMethotrimeprazine may increase the QTc-prolonging activities of Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Chlorphenamine.
ChlorphentermineMethotrimeprazine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineMethotrimeprazine may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe metabolism of Methotrimeprazine can be decreased when combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methotrimeprazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methotrimeprazine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Methotrimeprazine can be decreased when combined with Cholecalciferol.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Methotrimeprazine.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Methotrimeprazine.
CimetidineThe metabolism of Methotrimeprazine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Methotrimeprazine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methotrimeprazine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Methotrimeprazine.
CiprofloxacinMethotrimeprazine may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideMethotrimeprazine may increase the QTc-prolonging activities of Cisapride.
CitalopramThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Citalopram.
ClarithromycinMethotrimeprazine may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Methotrimeprazine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Methotrimeprazine.
ClidiniumThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Clidinium.
ClobazamThe metabolism of Methotrimeprazine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methotrimeprazine.
ClotrimazoleThe metabolism of Methotrimeprazine can be decreased when combined with Clotrimazole.
ClozapineMethotrimeprazine may increase the QTc-prolonging activities of Clozapine.
ClozapineThe metabolism of Methotrimeprazine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Methotrimeprazine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Methotrimeprazine.
CodeineMethotrimeprazine may increase the hypotensive activities of Codeine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methotrimeprazine.
CrizotinibMethotrimeprazine may increase the QTc-prolonging activities of Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methotrimeprazine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Methotrimeprazine.
CyproheptadineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Dantrolene.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Methotrimeprazine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methotrimeprazine.
DapoxetineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Dapoxetine.
DapsoneThe serum concentration of Methotrimeprazine can be increased when it is combined with Dapsone.
DarifenacinThe metabolism of Methotrimeprazine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Methotrimeprazine can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Methotrimeprazine.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Methotrimeprazine.
DelavirdineThe metabolism of Methotrimeprazine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methotrimeprazine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Methotrimeprazine.
DesloratadineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Methotrimeprazine.
DetomidineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Dexbrompheniramine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Methotrimeprazine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methotrimeprazine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Methotrimeprazine.
DextroamphetamineMethotrimeprazine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Methotrimeprazine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Methotrimeprazine.
DextromoramideMethotrimeprazine may increase the hypotensive activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methotrimeprazine.
DextropropoxypheneMethotrimeprazine may increase the hypotensive activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methotrimeprazine.
DezocineMethotrimeprazine may increase the hypotensive activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Methotrimeprazine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methotrimeprazine.
DifenoxinThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Difenoxin.
DihydrocodeineMethotrimeprazine may increase the hypotensive activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methotrimeprazine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methotrimeprazine.
DihydroetorphineMethotrimeprazine may increase the hypotensive activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methotrimeprazine.
DihydromorphineMethotrimeprazine may increase the hypotensive activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methotrimeprazine.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Methotrimeprazine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Methotrimeprazine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Diphenhydramine.
DiphenoxylateMethotrimeprazine may increase the hypotensive activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methotrimeprazine.
DisopyramideMethotrimeprazine may increase the QTc-prolonging activities of Disopyramide.
DofetilideMethotrimeprazine may increase the QTc-prolonging activities of Dofetilide.
DolasetronMethotrimeprazine may increase the QTc-prolonging activities of Dolasetron.
DomperidoneMethotrimeprazine may increase the QTc-prolonging activities of Domperidone.
DonepezilThe metabolism of Donepezil can be decreased when combined with Methotrimeprazine.
DopamineThe metabolism of Dopamine can be decreased when combined with Methotrimeprazine.
DoramectinThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Doramectin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Methotrimeprazine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Methotrimeprazine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Methotrimeprazine.
DoxycyclineThe serum concentration of Methotrimeprazine can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
DoxylamineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Doxylamine.
DPDPEMethotrimeprazine may increase the hypotensive activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Methotrimeprazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
DronedaroneMethotrimeprazine may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Methotrimeprazine can be decreased when combined with Dronedarone.
DroperidolMethotrimeprazine may increase the QTc-prolonging activities of Droperidol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Methotrimeprazine.
DrotebanolThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Drotebanol.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Methotrimeprazine.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Methotrimeprazine.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Methotrimeprazine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methotrimeprazine.
EcgonineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Methotrimeprazine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Methotrimeprazine.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Methotrimeprazine.
EliglustatThe metabolism of Methotrimeprazine can be decreased when combined with Eliglustat.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methotrimeprazine.
EncainideThe metabolism of Encainide can be decreased when combined with Methotrimeprazine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Methotrimeprazine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methotrimeprazine.
EntacaponeThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Entacapone.
EpinastineThe metabolism of Epinastine can be decreased when combined with Methotrimeprazine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Methotrimeprazine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Methotrimeprazine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Methotrimeprazine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Methotrimeprazine.
ErythromycinMethotrimeprazine may increase the QTc-prolonging activities of Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Escitalopram.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Methotrimeprazine.
EsmololMethotrimeprazine may increase the hypotensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Methotrimeprazine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methotrimeprazine.
EthanolMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Methotrimeprazine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methotrimeprazine.
EthosuximideThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ethyl loflazepate.
EthylmorphineMethotrimeprazine may increase the hypotensive activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methotrimeprazine.
EtidocaineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methotrimeprazine.
EtoperidoneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Etoperidone.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Methotrimeprazine.
EtorphineMethotrimeprazine may increase the hypotensive activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Methotrimeprazine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Methotrimeprazine.
EzogabineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fenfluramine.
FentanylMethotrimeprazine may increase the hypotensive activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methotrimeprazine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methotrimeprazine.
FexofenadineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fexofenadine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Methotrimeprazine.
FlecainideMethotrimeprazine may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methotrimeprazine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methotrimeprazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methotrimeprazine.
FluspirileneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Methotrimeprazine.
FluvoxamineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Methotrimeprazine.
FosphenytoinThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Methotrimeprazine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methotrimeprazine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with gabapentin enacarbil.
Gadobenic acidMethotrimeprazine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Methotrimeprazine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Methotrimeprazine.
GemifloxacinMethotrimeprazine may increase the QTc-prolonging activities of Gemifloxacin.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Methotrimeprazine.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Methotrimeprazine.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Methotrimeprazine.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Methotrimeprazine.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Methotrimeprazine.
GlutethimideThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Glutethimide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Methotrimeprazine.
GoserelinMethotrimeprazine may increase the QTc-prolonging activities of Goserelin.
GranisetronMethotrimeprazine may increase the QTc-prolonging activities of Granisetron.
GuanfacineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Methotrimeprazine.
HalofantrineThe serum concentration of Methotrimeprazine can be increased when it is combined with Halofantrine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Methotrimeprazine.
HaloperidolMethotrimeprazine may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe metabolism of Methotrimeprazine can be decreased when combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Methotrimeprazine.
HeroinMethotrimeprazine may increase the hypotensive activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Methotrimeprazine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methotrimeprazine.
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Methotrimeprazine resulting in a loss in efficacy.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methotrimeprazine.
HydromorphoneMethotrimeprazine may increase the hypotensive activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methotrimeprazine.
Hydroxyamphetamine hydrobromideMethotrimeprazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxychloroquineThe serum concentration of Methotrimeprazine can be increased when it is combined with Hydroxychloroquine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
HydroxyzineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Hydroxyzine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Methotrimeprazine.
IbutilideMethotrimeprazine may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Methotrimeprazine.
IloperidoneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Iloperidone.
ImatinibThe metabolism of Imatinib can be decreased when combined with Methotrimeprazine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Methotrimeprazine.
IndalpineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Indalpine.
IndenololMethotrimeprazine may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Methotrimeprazine can be decreased when combined with Indinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methotrimeprazine.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Methotrimeprazine.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methotrimeprazine.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Methotrimeprazine.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methotrimeprazine.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methotrimeprazine.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Methotrimeprazine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methotrimeprazine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methotrimeprazine.
IsoniazidThe metabolism of Methotrimeprazine can be decreased when combined with Isoniazid.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Methotrimeprazine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methotrimeprazine.
KetazolamThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ketazolam.
KetobemidoneMethotrimeprazine may increase the hypotensive activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methotrimeprazine.
KetoconazoleThe metabolism of Methotrimeprazine can be decreased when combined with Ketoconazole.
LabetalolMethotrimeprazine may increase the hypotensive activities of Labetalol.
LamotrigineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Lamotrigine.
LenvatinibMethotrimeprazine may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideMethotrimeprazine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Levetiracetam.
LevobunololMethotrimeprazine may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Methotrimeprazine.
LevocabastineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Levodopa.
LevofloxacinMethotrimeprazine may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateMethotrimeprazine may increase the hypotensive activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methotrimeprazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Levomilnacipran.
LevorphanolMethotrimeprazine may increase the hypotensive activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methotrimeprazine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methotrimeprazine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Methotrimeprazine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Methotrimeprazine.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Methotrimeprazine.
LisdexamfetamineMethotrimeprazine may decrease the stimulatory activities of Lisdexamfetamine.
LisurideThe metabolism of Lisuride can be decreased when combined with Methotrimeprazine.
LithiumLithium may increase the neurotoxic activities of Methotrimeprazine.
LithiumThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Lithium.
LofentanilMethotrimeprazine may increase the hypotensive activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Methotrimeprazine.
LomustineThe metabolism of Lomustine can be decreased when combined with Methotrimeprazine.
LoperamideThe metabolism of Loperamide can be decreased when combined with Methotrimeprazine.
LopinavirMethotrimeprazine may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe metabolism of Methotrimeprazine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methotrimeprazine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Methotrimeprazine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Methotrimeprazine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methotrimeprazine.
Lu AA21004The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Lu AA21004.
LumefantrineThe serum concentration of Methotrimeprazine can be increased when it is combined with Lumefantrine.
LumefantrineMethotrimeprazine may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Lurasidone.
MagaldrateMagaldrate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Magnesium Sulfate.
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methotrimeprazine.
MeclizineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Medetomidine.
MefloquineThe serum concentration of Methotrimeprazine can be increased when it is combined with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Methotrimeprazine.
MelperoneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Melperone.
MephentermineMethotrimeprazine may decrease the stimulatory activities of Mephentermine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Methotrimeprazine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methotrimeprazine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methotrimeprazine.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Methotrimeprazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methotrimeprazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Metaxalone.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Methotrimeprazine.
MethadoneMethotrimeprazine may increase the hypotensive activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methotrimeprazine.
Methadyl AcetateMethotrimeprazine may increase the hypotensive activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Methotrimeprazine.
MethamphetamineMethotrimeprazine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methotrimeprazine.
MethsuximideThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methotrimeprazine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Methotrimeprazine.
MetipranololMethotrimeprazine may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Methotrimeprazine.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Methotrimeprazine.
MetoprololMethotrimeprazine may increase the hypotensive activities of Metoprolol.
MetoprololThe metabolism of Methotrimeprazine can be decreased when combined with Metoprolol.
MetyrosineMethotrimeprazine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Methotrimeprazine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Methotrimeprazine.
MianserinThe metabolism of Mianserin can be decreased when combined with Methotrimeprazine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methotrimeprazine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Methotrimeprazine.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Methotrimeprazine.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Methotrimeprazine.
MilnacipranThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Milnacipran.
MinaprineThe metabolism of Minaprine can be decreased when combined with Methotrimeprazine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MirabegronThe metabolism of Methotrimeprazine can be decreased when combined with Mirabegron.
MirtazapineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methotrimeprazine.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Methotrimeprazine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Methotrimeprazine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Methotrimeprazine.
MolindoneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Molindone.
MorphineMethotrimeprazine may increase the hypotensive activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methotrimeprazine.
MoxifloxacinMethotrimeprazine may increase the QTc-prolonging activities of Moxifloxacin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
NabiloneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Nabilone.
NadololMethotrimeprazine may increase the hypotensive activities of Nadolol.
NalbuphineMethotrimeprazine may increase the hypotensive activities of Nalbuphine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methotrimeprazine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Methotrimeprazine.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Methotrimeprazine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Methotrimeprazine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Methotrimeprazine.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Methotrimeprazine.
NetupitantThe metabolism of Netupitant can be decreased when combined with Methotrimeprazine.
NevirapineThe metabolism of Methotrimeprazine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Methotrimeprazine can be decreased when combined with Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Methotrimeprazine.
NicotineThe metabolism of Nicotine can be decreased when combined with Methotrimeprazine.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Methotrimeprazine.
NilotinibMethotrimeprazine may increase the QTc-prolonging activities of Nilotinib.
NilotinibThe metabolism of Methotrimeprazine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Nitrazepam.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Methotrimeprazine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Nitrous oxide.
NormethadoneMethotrimeprazine may increase the hypotensive activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Methotrimeprazine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Methotrimeprazine.
OfloxacinMethotrimeprazine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Olopatadine.
OndansetronMethotrimeprazine may increase the QTc-prolonging activities of Ondansetron.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methotrimeprazine.
OpiumMethotrimeprazine may increase the hypotensive activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Methotrimeprazine.
OrphenadrineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methotrimeprazine.
OsanetantThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methotrimeprazine.
OxprenololMethotrimeprazine may increase the hypotensive activities of Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methotrimeprazine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methotrimeprazine.
OxycodoneMethotrimeprazine may increase the hypotensive activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methotrimeprazine.
OxymorphoneMethotrimeprazine may increase the hypotensive activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methotrimeprazine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methotrimeprazine.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Methotrimeprazine.
PanobinostatMethotrimeprazine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Methotrimeprazine can be decreased when combined with Panobinostat.
ParaldehydeMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Methotrimeprazine.
ParoxetineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Paroxetine.
PazopanibMethotrimeprazine may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Methotrimeprazine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololMethotrimeprazine may increase the hypotensive activities of Penbutolol.
PentamidineMethotrimeprazine may increase the QTc-prolonging activities of Pentamidine.
PentazocineMethotrimeprazine may increase the hypotensive activities of Pentazocine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methotrimeprazine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methotrimeprazine.
PerampanelThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Perampanel.
PerflutrenMethotrimeprazine may increase the QTc-prolonging activities of Perflutren.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Methotrimeprazine.
PerospironeThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methotrimeprazine.
PethidineMethotrimeprazine may increase the hypotensive activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methotrimeprazine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Methotrimeprazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methotrimeprazine.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Methotrimeprazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methotrimeprazine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Phenoxyethanol.
PhentermineMethotrimeprazine may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Phenytoin.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Methotrimeprazine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methotrimeprazine.
PindololMethotrimeprazine may increase the hypotensive activities of Pindolol.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methotrimeprazine.
PipamperoneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Pipamperone.
PiperazineThe metabolism of Piperazine can be decreased when combined with Methotrimeprazine.
PipotiazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Pomalidomide.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Methotrimeprazine.
PractololMethotrimeprazine may increase the hypotensive activities of Practolol.
PramipexoleMethotrimeprazine may increase the sedative activities of Pramipexole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Methotrimeprazine.
PramocaineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methotrimeprazine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Methotrimeprazine.
PrimaquineThe serum concentration of Methotrimeprazine can be increased when it is combined with Primaquine.
PrimaquineMethotrimeprazine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Primidone.
ProcainamideMethotrimeprazine may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Methotrimeprazine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Methotrimeprazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methotrimeprazine.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Methotrimeprazine.
ProguanilThe serum concentration of Methotrimeprazine can be increased when it is combined with Proguanil.
PromazineMethotrimeprazine may increase the QTc-prolonging activities of Promazine.
PromazineThe metabolism of Methotrimeprazine can be decreased when combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Methotrimeprazine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Methotrimeprazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methotrimeprazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methotrimeprazine.
PropoxycaineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Propoxycaine.
PropranololMethotrimeprazine may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methotrimeprazine.
PSD502The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with PSD502.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Methotrimeprazine.
PyrimethamineThe serum concentration of Methotrimeprazine can be increased when it is combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methotrimeprazine.
QuinacrineThe serum concentration of Methotrimeprazine can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Methotrimeprazine.
QuinidineThe serum concentration of Methotrimeprazine can be increased when it is combined with Quinidine.
QuinidineMethotrimeprazine may increase the QTc-prolonging activities of Quinidine.
QuinineThe serum concentration of Methotrimeprazine can be increased when it is combined with Quinine.
QuinineMethotrimeprazine may increase the QTc-prolonging activities of Quinine.
RadicicolThe serum concentration of Methotrimeprazine can be increased when it is combined with Radicicol.
RamelteonThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ramelteon.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Methotrimeprazine.
RanolazineThe metabolism of Methotrimeprazine can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methotrimeprazine.
RemifentanilMethotrimeprazine may increase the hypotensive activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methotrimeprazine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methotrimeprazine.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Methotrimeprazine.
repinotanThe metabolism of repinotan can be decreased when combined with Methotrimeprazine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methotrimeprazine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methotrimeprazine.
RitonavirThe metabolism of Methotrimeprazine can be decreased when combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Methotrimeprazine.
RolapitantThe metabolism of Methotrimeprazine can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Romifidine.
RopiniroleMethotrimeprazine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Methotrimeprazine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methotrimeprazine.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methotrimeprazine.
RotigotineMethotrimeprazine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methotrimeprazine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with S-Ethylisothiourea.
SaquinavirMethotrimeprazine may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methotrimeprazine.
ScopolamineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methotrimeprazine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Methotrimeprazine.
SertindoleThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methotrimeprazine.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Methotrimeprazine.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Methotrimeprazine.
SinefunginThe serum concentration of Methotrimeprazine can be increased when it is combined with Sinefungin.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methotrimeprazine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Sodium oxybate.
SotalolMethotrimeprazine may increase the hypotensive activities of Sotalol.
SparteineThe metabolism of Sparteine can be decreased when combined with Methotrimeprazine.
StiripentolThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Stiripentol.
SufentanilMethotrimeprazine may increase the hypotensive activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methotrimeprazine.
SulfadoxineThe serum concentration of Methotrimeprazine can be increased when it is combined with Sulfadoxine.
SulfametopyrazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Sulfametopyrazine.
SulfisoxazoleMethotrimeprazine may increase the QTc-prolonging activities of Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Methotrimeprazine.
SulpirideThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Methotrimeprazine.
SuvorexantThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Suvorexant.
tafenoquineThe serum concentration of Methotrimeprazine can be increased when it is combined with tafenoquine.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Methotrimeprazine resulting in a loss in efficacy.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Methotrimeprazine.
TapentadolMethotrimeprazine may increase the hypotensive activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Methotrimeprazine.
TasimelteonThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Methotrimeprazine.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Methotrimeprazine.
TelavancinMethotrimeprazine may increase the QTc-prolonging activities of Telavancin.
TelithromycinMethotrimeprazine may increase the QTc-prolonging activities of Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methotrimeprazine.
TerbinafineThe metabolism of Methotrimeprazine can be decreased when combined with Terbinafine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Methotrimeprazine.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Methotrimeprazine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Methotrimeprazine.
TetracaineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Tetrodotoxin.
ThalidomideMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methotrimeprazine.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Methotrimeprazine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methotrimeprazine.
ThiopentalThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Thiopental.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Methotrimeprazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methotrimeprazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Tiagabine.
TiclopidineThe metabolism of Methotrimeprazine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Tiletamine.
TimololMethotrimeprazine may increase the hypotensive activities of Timolol.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Methotrimeprazine.
TipranavirThe metabolism of Methotrimeprazine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Tizanidine.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Methotrimeprazine.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methotrimeprazine.
TolcaponeThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Tolcapone.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Methotrimeprazine.
TopiramateThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Topiramate.
ToremifeneMethotrimeprazine may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Methotrimeprazine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Methotrimeprazine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methotrimeprazine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methotrimeprazine.
TrazodoneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Methotrimeprazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methotrimeprazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methotrimeprazine.
TrimethoprimThe serum concentration of Methotrimeprazine can be increased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Methotrimeprazine.
TriprolidineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Triprolidine.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Methotrimeprazine.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Methotrimeprazine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methotrimeprazine.
VandetanibMethotrimeprazine may increase the QTc-prolonging activities of Vandetanib.
VemurafenibMethotrimeprazine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Methotrimeprazine.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Methotrimeprazine.
VigabatrinThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Vilazodone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methotrimeprazine.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Methotrimeprazine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Methotrimeprazine.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Methotrimeprazine.
VortioxetineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Xylazine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Methotrimeprazine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Methotrimeprazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methotrimeprazine.
ZiconotideThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Zimelidine.
ZiprasidoneThe metabolism of Methotrimeprazine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Methotrimeprazine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methotrimeprazine.
ZonisamideThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Methotrimeprazine.
ZotepineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Zuclopenthixol.
Food Interactions
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  2. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  2. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  2. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  2. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  2. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  3. Tsukamoto T, Asakura M, Hirata N, Imafuku J, Matsui H, Hasegawa K: Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. [PubMed:6149771 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  3. Tsukamoto T, Asakura M, Hirata N, Imafuku J, Matsui H, Hasegawa K: Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. [PubMed:6149771 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716 ]
  3. Tsukamoto T, Asakura M, Hirata N, Imafuku J, Matsui H, Hasegawa K: Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. [PubMed:6149771 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205 ]
Comments
comments powered by Disqus
Drug created on July 10, 2007 12:38 / Updated on August 17, 2016 12:23